| Bioactivity | TX-2552 is an orally active tyrosine DNA phosphodiesterase 1 (TDP1) inhibitor with an IC50 value of 0.62 μM. TX-2552 can enhance the clastogenic activity of Topotecan (HY-13768) in mouse bone marrow cells, as well as the anti-tumor effect of Topotecan (HY-13768) in Krebs-2 ascites tumor mice[1][2]. |
| Target | TDP1. |
| In Vivo | TX-2552 (20-160 mg/kg; 口服) 可以在骨髓细胞染色体畸变小鼠中增强拓扑替康 (HY-13768) 的致裂作用[1]。TX-2552 (20-120 mg/kg; 每天 1 次; 18 天; 腹腔注射) 可以增强拓扑替康 (HY-13768) 在 Krebs-2 腹水瘤小鼠中的抗肿瘤作用[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 2446767-14-0 |
| Formula | C25H25FO3 |
| Molar Mass | 392.46 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhanataev AK, et al. Enhancement of the Clastogenic Effects of Topotecan In Vivo by Tyrosyl-DNA Phosphodiesterase 1 Inhibitors. Bull Exp Biol Med. 2024 May;177(1):30-34. [2]. Khomenko TM, et al. Promising New Inhibitors of Tyrosyl-DNA Phosphodiesterase I (Tdp 1) Combining 4-Arylcoumarin and Monoterpenoid Moieties as Components of Complex Antitumor Therapy. Int J Mol Sci. 2019 Dec 23;21(1):126. |